TICKERNERD
Menu
BOLTBOLTHealthcare · Biotechnology

BOLT Stock Forecast: Bolt Biotherapeutics, Inc. Price Predictions for 2026-2027

Last close, 21 Aug 2026
$3.73
+16.56% on the day

The 4 Wall Street analysts covering Bolt Biotherapeutics, Inc. hold a median 12-month price target of $7 — +87.7% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 73 of 100 as at 22 Aug 2026 — in the upper half. Here, the model and the Street point the same way.

Market cap
$7.1M
Ticker Nerd rank
73 / 100
Median analyst target
$7.00
Analysts covering
4
Total return, dividends reinvested
1W
+11.3%
1M
−7.2%
YTD
−31.8%
1Y
−23.7%
From 52W high
−47.4%
From 52W low
+17.4%
$3.18
$7.09
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

BOLT stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Bolt Biotherapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 22 Aug 2026
73 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Growth
99
Volatility
94
Size
94
Issuance
89
Accruals
64
Quality
54
Value
41
Revisions
27
Momentum
16

Growth (99): Sales and profits are climbing, and climbing faster than before.

Momentum (16): The shares have been drifting down relative to others.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

BOLT stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on BOLT, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.00$20.00$40.00$60.00$80.00Oct 25Jan 26Apr 26Jul 26BOLTHigh $75.00Median $7.00Low $5.00

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says4 analysts
2 Buy2 Hold0 Sell
Low $5.00Median $7.00High $75.00

The green dot is the last close — the median target sits +87.7% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
29 May 2026Rodman & RenshawInitiatesBuy$22
28 May 2026HC Wainwright & Co.ReiteratesBuy$7.00
13 Mar 2026HC Wainwright & Co.ReiteratesBuy—
20 Oct 2025HC Wainwright & Co.AssumesBuy$7.00
15 Aug 2025Lake StreetMaintainsBuy—
20 May 2025Lake StreetInitiatesBuy—
13 May 2025StifelMaintainsHold—
25 Mar 2025HC Wainwright & Co.ReiteratesNeutral—
25 Mar 2025StifelMaintainsHold—
13 Nov 2024HC Wainwright & Co.ReiteratesNeutral—
15 Aug 2024HC Wainwright & Co.ReiteratesNeutral—
15 May 2024GuggenheimDowngradeNeutral—
15 May 2024HC Wainwright & Co.DowngradeNeutral—
15 May 2024Jones TradingDowngradeHold—
15 May 2024Leerink PartnersDowngradeMarket Perform—
15 May 2024StifelDowngradeHold—
22 Mar 2024HC Wainwright & Co.MaintainsBuy—
8 Aug 2023HC Wainwright & Co.ReiteratesBuy—
3 Aug 2023HC Wainwright & Co.ReiteratesBuy—
5 June 2023HC Wainwright & Co.ReiteratesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. BOLT appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

BOLT analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
0
Analysts cutting
0
Fundamentals

Bolt Biotherapeutics, Inc. (BOLT) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−0.2×

Cheaper than 78% of US stocks

Price / sales
1.5×

Cheaper than 60% of US stocks

Price / book
0.6×

Cheaper than 84% of US stocks

EV / EBITDA
−0.4×

Cheaper than 63% of US stocks

Growth & margins
Revenue growth (YoY)
−99.7%

Higher than 1% of US stocks

Earnings growth (YoY)
−97.9%

Higher than 2% of US stocks

Gross margin
—
Operating margin
−151320.0%

Higher than 1% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−111.6%

Higher than 12% of US stocks

Return on assets
−30.7%

Higher than 14% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

BOLT vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
BOLTBolt Biotherapeutics, Inc.$7.1M
73
NIKINiki Biosolutions, Inc.$7.0M
12
LIMNLiminatus Pharma, Inc.$6.9M
10
KAPAKairos Pharma Ltd.$6.9M
38
ENSCEnsysce Biosciences, Inc.$7.3M
41
XCURExicure, Inc.$7.3M
46
CURXCuranex Pharmaceuticals, Inc.$7.4M
5

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Bolt Biotherapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest BOLT news & analysis

Bolt Biotherapeutics, Inc. (BOLT) Reports Q2 Loss, Misses Revenue Estimates

Zacks Investment Research · 11 Aug 2026negative

Bolt Biotherapeutics reported a quarterly loss of $4.57 per share, wider than the Zacks Consensus Estimate of a $2.97 loss and slightly larger than the $4.46 per share loss a year ago. The company also missed revenue estimates for the quarter.

Why it matters — BOLT watchers would care because the quarterly loss came in well above consensus expectations while revenue fell short of estimates, signalling weaker-than-anticipated performance.

Bolt Biotherapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update

GlobeNewsWire · 11 Aug 2026neutral

Bolt Biotherapeutics reported financial results for the second quarter ended June 30, 2026, and provided a business update. The company's Phase 1/2 study of its first-in-class immune-stimulating antibody conjugate BDC-4182 is ongoing, with initial clinical data expected alongside its third-quarter 2026 results, and its cash balance of $18.1 million is anticipated to fund operations into the first quarter of 2027.

Why it matters — Bolt watchers would care because the report covers the status of its lead candidate BDC-4182, the timeline for initial clinical data, and its cash runway into early 2027.

FAQ

Frequently asked questions about BOLT stock

What is the BOLT stock price forecast for 2026-2027?

The 4 Wall Street analysts covering Bolt Biotherapeutics, Inc. have a median 12-month price target of $7, with estimates ranging from $5 to $75. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is BOLT stock a buy right now?

Of the 4 analysts covering Bolt Biotherapeutics, Inc., 2 rate it a Buy, 2 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Bolt Biotherapeutics, Inc. 73 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank BOLT?

As at 22 Aug 2026, Bolt Biotherapeutics, Inc. ranks 73 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Growth (99 of 100).

Will BOLT stock go up?

No one can know that. What the data says: the median 12-month target from 4 analysts implies +87.7% from the last close, and Ticker Nerd's factor model ranks Bolt Biotherapeutics, Inc. 73 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the BOLT stock forecast for 2030?

No analyst covering Bolt Biotherapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for BOLT are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $5 to $75 over the next 12 months.

How has BOLT stock performed over the past year?

Bolt Biotherapeutics, Inc. returned -23.7% over the 12 months to 21 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Bolt Biotherapeutics, Inc. do?

Bolt Biotherapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing novel immunotherapies for cancer treatment.

What is the latest news on BOLT?

The most recent item we track (Zacks Investment Research, 11 Aug 2026): "Bolt Biotherapeutics, Inc. (BOLT) Reports Q2 Loss, Misses Revenue Estimates". Bolt Biotherapeutics reported a quarterly loss of $4.57 per share, wider than the Zacks Consensus Estimate of a $2.97 loss and slightly larger than the $4.46 per share loss a year ago. The company also missed revenue estimates for the quarter.

Company

About Bolt Biotherapeutics, Inc.

Bolt Biotherapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing novel immunotherapies for cancer treatment. The company harnesses the immune system through its proprietary Boltbody Immune-Stimulating Antibody Conjugate (ISAC) platform, which combines tumor-targeting antibodies with immune-stimulating linker-payloads to activate both innate and adaptive immune responses against tumors. Key pipeline candidates include BDC-1001, targeting HER2-positive solid tumors such as breast, colorectal, endometrial, and gastroesophageal cancers; BDC-3042, an agonist antibody targeting Dectin-2 on tumor-associated macrophages for tumors like head and neck, non-small cell lung, ovarian, and triple-negative breast cancers; and BDC-4182, a next-generation ISAC targeting claudin 18.2, overexpressed in gastric, gastroesophageal junction, and pancreatic cancers. Bolt Biotherapeutics Inc. maintains collaborations with partners including Toray Industries, Genmab, and Innovent Biologics to advance its ISAC technologies. Incorporated in 2015 and headquartered in Redwood City, California, the company operates in the biotechnology sector of healthcare, emphasizing myeloid biology and immuno-oncology drug development.

CEO Mr. William P. Quinn · 52 employees · United States · https://www.boltbio.com